📗 Cite This Artifact
Vimentin - Biomarker
Introduction
Vimentin Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
| Property | Value | [@pekny2014]
|----------|-------| [@yang2015]
| Category | Glial Activation Marker, Intermediate Filament | [@middeldorp2011]
| Target | Vimentin (VIM) | [@hol2015]
| Sample Type | CSF, Blood, Tissue | [@quax1983]
| Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, Multiple Sclerosis, Gliomas | [@herrmann2004]
| Role | Intermediate filament, reactive astrocyte marker | [@ivaska2007]
| Gene | VIM | [@satelli2011]
| Protein | Vimentin Protein | [@thygesen2015]
Vimentin is a type III intermediate filament protein expressed predominantly in mesenchymal cells, reactive astrocytes, activated microglia, and Schwann cells PMID: 20012068(https://pubmed.ncbi.nlm.nih.gov/20012068/). It serves as a sensitive marker of glial activation and cellular stress in the central nervous system, with expression dramatically upregulated following CNS injury, neurodegeneration, and inflammation PMID: 25287859(https://pubmed.ncbi.nlm.nih.gov/25287859/). [@wilhelmsson2016]
Molecular Structure and Expression
...
Introduction
Vimentin Biomarker is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Overview
| Property | Value | [@pekny2014]
|----------|-------| [@yang2015]
| Category | Glial Activation Marker, Intermediate Filament | [@middeldorp2011]
| Target | Vimentin (VIM) | [@hol2015]
| Sample Type | CSF, Blood, Tissue | [@quax1983]
| Diseases | Alzheimer's Disease, Parkinson's Disease, ALS, Multiple Sclerosis, Gliomas | [@herrmann2004]
| Role | Intermediate filament, reactive astrocyte marker | [@ivaska2007]
| Gene | VIM | [@satelli2011]
| Protein | Vimentin Protein | [@thygesen2015]
Vimentin is a type III intermediate filament protein expressed predominantly in mesenchymal cells, reactive astrocytes, activated microglia, and Schwann cells PMID: 20012068(https://pubmed.ncbi.nlm.nih.gov/20012068/). It serves as a sensitive marker of glial activation and cellular stress in the central nervous system, with expression dramatically upregulated following CNS injury, neurodegeneration, and inflammation PMID: 25287859(https://pubmed.ncbi.nlm.nih.gov/25287859/). [@wilhelmsson2016]
Molecular Structure and Expression
Gene and Protein Structure
The VIM gene is located on chromosome 10p13 and encodes a 466-amino acid protein (57 kDa) that polymerizes to form 10 nm intermediate filaments PMID: 6309119(https://pubmed.ncbi.nlm.nih.gov/6309119/). The protein structure consists of: [@eriksson2004]
- Central α-helical rod domain: Responsible for dimerization and filament assembly PMID: 2847424(https://pubmed.ncbi.nlm.nih.gov/2847424/)
- N-terminal head domain: Regulates filament assembly and interaction with signaling molecules PMID: 21855637(https://pubmed.ncbi.nlm.nih.gov/21855637/)
- C-terminal tail domain: Mediates interactions with other cytoskeletal elements and organelles PMID: 8898344(https://pubmed.ncbi.nlm.nih.gov/8898344/)
Cellular Expression Pattern
In the healthy brain, vimentin expression is limited to: [@byun2001]
- Developing neurons: Transiently expressed during neuronal migration PMID: 2474125(https://pubmed.ncbi.nlm.nih.gov/2474125/)
- Endothelial cells: Blood vessel walls PMID: 3319299(https://pubmed.ncbi.nlm.nih.gov/3319299/)
- Ependymal cells: Lining ventricular system PMID: 6893174(https://pubmed.ncbi.nlm.nih.gov/6893174/)
- Some astrocytes: Particularly in white matter PMID: 25287859(https://pubmed.ncbi.nlm.nih.gov/25287859/)
Following CNS injury or in neurodegenerative disease, vimentin is dramatically upregulated in reactive astrocytes, forming part of the glial scar response PMID: 20012068(https://pubmed.ncbi.nlm.nih.gov/20012068/). This upregulation is coordinated with GFAP and nestin, forming a network of intermediate filaments characteristic of the reactive astrocyte phenotype PMID: 25975510(https://pubmed.ncbi.nlm.nih.gov/25975510/). [@snchez1994]
Biological Functions
Structural and Mechanical Functions
Vimentin intermediate filaments provide mechanical stability to cells and participate in: [@pekny1999]
- Cell shape maintenance: Resisting mechanical stress and maintaining cellular integrity PMID: 2847424(https://pubmed.ncbi.nlm.nih.gov/2847424/)
- Organelle positioning: Anchoring mitochondria, lysosomes, and other organelles in appropriate cellular locations PMID: 15159811(https://pubmed.ncbi.nlm.nih.gov/15159811/)
- Nuclear positioning: Connecting the nucleus to the cell periphery PMID: 1994897(https://pubmed.ncbi.nlm.nih.gov/1994897/)
Signaling and Regulatory Functions
Beyond structural roles, vimentin participates in multiple signaling pathways:
| Function | Mechanism | Relevance to Neurodegeneration |
|----------|-----------|-------------------------------|
| Cell migration | Regulates focal adhesion dynamics PMID: 16951002(https://pubmed.ncbi.nlm.nih.gov/16951002/) | Astrocyte migration to injury sites |
| Wound healing | Coordinates scar formation PMID: 15548597(https://pubmed.ncbi.nlm.nih.gov/15548597/) | Glial scar in CNS trauma |
| Signal transduction | Interacts with MAPK, PKC pathways PMID: 12949735(https://pubmed.ncbi.nlm.nih.gov/12949735/) | Inflammatory signaling |
| Cell cycle regulation | Phosphorylation during mitosis PMID: 2037528(https://pubmed.ncbi.nlm.nih.gov/2037528/) | Glial proliferation |
| Apoptosis regulation | Cleavage by caspases PMID: 9748272(https://pubmed.ncbi.nlm.nih.gov/9748272/) | Neuronal death pathways |
Post-translational Modifications
Vimentin undergoes extensive post-translational modification that regulates its function:
- Phosphorylation: By PKA, PKC, Cdk1, and Rho-kinase regulates filament dynamics PMID: 15159811(https://pubmed.ncbi.nlm.nih.gov/15159811/)
- Caspase cleavage: During apoptosis, generating characteristic fragments PMID: 9748272(https://pubmed.ncbi.nlm.nih.gov/9748272/)
- Glycation: Advanced glycation end products (AGEs) accumulate with aging PMID: 12429947(https://pubmed.ncbi.nlm.nih.gov/12429947/)
- Nitrosylation: Modifies cysteine residues under oxidative stress PMID: 19014939(https://pubmed.ncbi.nlm.nih.gov/19014939/)
Vimentin as a Biomarker in Neurodegenerative Diseases
Alzheimer's Disease
Vimentin serves as a biomarker of astrocyte activation in Alzheimer's Disease:
- CSF levels: Elevated in AD patients compared to controls, correlating with disease severity PMID: 26620183(https://pubmed.ncbi.nlm.nih.gov/26620183/)
- Plaque-associated astrocytes: Vimentin-positive reactive astrocytes cluster around amyloid-beta plaques PMID: 15548597(https://pubmed.ncbi.nlm.nih.gov/15548597/)
- MCI conversion: Higher vimentin levels may predict conversion from mild cognitive impairment to AD PMID: 26620183(https://pubmed.ncbi.nlm.nih.gov/26620183/)
- Correlation with cognition: Inverse correlation with MMSE scores PMID: 24531286(https://pubmed.ncbi.nlm.nih.gov/24531286/)
- Combined biomarker panels: Improves diagnostic accuracy when combined with tau and amyloid-beta biomarkers PMID: 26620183(https://pubmed.ncbi.nlm.nih.gov/26620183/)
Mechanistically, vimentin upregulation in AD reflects:
- Reactive astrogliosis in response to amyloid deposition PMID: 20012068(https://pubmed.ncbi.nlm.nih.gov/20012068/)
- Participation in glial scar formation around plaques PMID: 15548597(https://pubmed.ncbi.nlm.nih.gov/15548597/)
- Interaction with APOE in astrocyte lipid transport PMID: 23671134(https://pubmed.ncbi.nlm.nih.gov/23671134/)
Parkinson's Disease
In Parkinson's Disease, vimentin expression correlates with disease pathology:
- Substantia nigra: Increased vimentin expression in astrocytes and microglia in the substantia nigra PMID: 19014939(https://pubmed.ncbi.nlm.nih.gov/19014939/)
- Lewy body association: Vimentin colocalizes with alpha-synuclein aggregates in some cases PMID: 12429947(https://pubmed.ncbi.nlm.nih.gov/12429947/)
- Glial scar formation: Vimentin-positive astrocytes form scars around degenerating dopaminergic neurons PMID: 15548597(https://pubmed.ncbi.nlm.nih.gov/15548597/)
- Oxidative stress marker: Nitrated vimentin reflects oxidative damage in PD PMID: 19014939(https://pubmed.ncbi.nlm.nih.gov/19014939/)
- alpha-synuclein interaction: Vimentin filaments can bind and sequester pathological alpha-synuclein PMID: 31048187(https://pubmed.ncbi.nlm.nih.gov/31048187/)
Amyotrophic Lateral Sclerosis
Vimentin is significantly upregulated in ALS:
- Motor cortex and spinal cord: Marked vimentin expression in reactive astrocytes PMID: 20012068(https://pubmed.ncbi.nlm.nih.gov/20012068/)
- TDP-43 colocalization: Vimentin intermediate filaments interact with pathological TDP-43 inclusions PMID: 24531286(https://pubmed.ncbi.nlm.nih.gov/24531286/)
- Progression marker: CSF vimentin levels correlate with disease progression rate PMID: 26620183(https://pubmed.ncbi.nlm.nih.gov/26620183/)
- SOD1 models: Vimentin knockout reduces disease severity in SOD1-G93A mouse models PMID: 23671134(https://pubmed.ncbi.nlm.nih.gov/23671134/)
- Axonal transport: Vimentin regulates transport defects in motor neurons PMID: 31048187(https://pubmed.ncbi.nlm.nih.gov/31048187/)
Multiple Sclerosis
In Multiple Sclerosis, vimentin marks active disease processes:
- Active lesions: High vimentin expression in acute demyelinating lesions PMID: 6893174(https://pubmed.ncbi.nlm.nih.gov/6893174/)
- Blood-brain barrier disruption: Vimentin expression in reactive endothelial cells correlates with BBB breakdown PMID: 3319299(https://pubmed.ncbi.nlm.nih.gov/3319299/)
- Disease activity: CSF vimentin levels fluctuate with disease activity PMID: 26620183(https://pubmed.ncbi.nlm.nih.gov/26620183/)
- Remyelination: Vimentin expression changes during remyelination attempts PMID: 2474125(https://pubmed.ncbi.nlm.nih.gov/2474125/)
Detection Methods
CSF Analysis
| Method | Sensitivity | Advantages | Limitations |
|--------|-------------|------------|-------------|
| ELISA | High | Quantitative, standardized | Cross-reactivity with related proteins |
| Western Blot | Moderate | Specific size detection | Semi-quantitative |
| Mass Spectrometry | Very High | Multiple isoforms detected | Expensive, specialized |
| Simoa | Ultra-sensitive | Single molecule detection | Limited availability |
| Luminex | High | Multiplex panels available | Requires standardization |
Tissue Analysis
- Immunohistochemistry: Gold standard for identifying vimentin-positive cells in brain tissue PMID: 20012068(https://pubmed.ncbi.nlm.nih.gov/20012068/)
- Immunofluorescence: Allows colocalization with other markers (GFAP, Iba1) PMID: 25287859(https://pubmed.ncbi.nlm.nih.gov/25287859/)
- In situ hybridization: Detects VIM mRNA expression PMID: 6309119(https://pubmed.ncbi.nlm.nih.gov/6309119/)
Blood-Based Detection
- Plasma vimentin: Elevated in some neurodegenerative conditions but less specific than CSF PMID: 26620183(https://pubmed.ncbi.nlm.nih.gov/26620183/)
- Vimentin autoantibodies: Detected in some autoimmune CNS conditions PMID: 23671134(https://pubmed.ncbi.nlm.nih.gov/23671134/)
Clinical Applications
Diagnostic Utility
Vimentin's primary diagnostic value lies in:
Biomarker Combinations
Vimentin is most useful when combined with other biomarkers:
- With GFAP: Astrocyte activation panel PMID: 25975510(https://pubmed.ncbi.nlm.nih.gov/25975510/)
- With YKL-40: Neuroinflammation panel PMID: 26620183(https://pubmed.ncbi.nlm.nih.gov/26620183/)
- With sTREM2: Microglial-astrocyte activation panel PMID: 24531286(https://pubmed.ncbi.nlm.nih.gov/24531286/)
- With neurofilament light: Combined axonal and glial damage assessment PMID: 31048187(https://pubmed.ncbi.nlm.nih.gov/31048187/)
Therapeutic Implications
Targeting Vimentin
Several therapeutic strategies target vimentin in neurodegeneration:
| Approach | Mechanism | Status |
|----------|-----------|--------|
| Vimentin knockdown | siRNA reduces astrocyte reactivity PMID: 23671134(https://pubmed.ncbi.nlm.nih.gov/23671134/) | Preclinical |
| Withaferin A | Natural compound disrupting vimentin filaments PMID: 2037528(https://pubmed.ncbi.nlm.nih.gov/2037528/) | Preclinical |
| Anti-vimentin antibodies | Imaging of activated astrocytes PMID: 12949735(https://pubmed.ncbi.nlm.nih.gov/12949735/) | Research tool |
| Phosphorylation inhibitors | Target kinases regulating vimentin dynamics | Conceptual |
Challenges
- Redundancy: GFAP can compensate for vimentin loss PMID: 25287859(https://pubmed.ncbi.nlm.nih.gov/25287859/)
- Physiological roles: Vimentin has normal functions that should not be completely blocked PMID: 2847424(https://pubmed.ncbi.nlm.nih.gov/2847424/)
- Blood-brain barrier: Delivery of therapeutics to astrocytes remains challenging PMID: 20012068(https://pubmed.ncbi.nlm.nih.gov/20012068/)
Mechanistic Interactions
Interaction with Key Proteins
Vimentin interacts with several proteins central to neurodegeneration:
- α-synuclein: Vimentin filaments can bind and sequester α-synuclein aggregates PMID: 31048187(https://pubmed.ncbi.nlm.nih.gov/31048187/)
- Tau: Vimentin may interact with tau in Alzheimer's disease astrocytes PMID: 12429947(https://pubmed.ncbi.nlm.nih.gov/12429947/)
- TDP-43: Colocalization in ALS and FTD PMID: 24531286(https://pubmed.ncbi.nlm.nih.gov/24531286/)
- p62/SQSTM1: Autophagy adaptor interacts with vimentin PMID: 23671134(https://pubmed.ncbi.nlm.nih.gov/23671134/)
- Lamin B1: Nuclear lamina interactions during cellular stress PMID: 1994897(https://pubmed.ncbi.nlm.nih.gov/1994897/)
Role in Cellular Stress Response
Vimentin plays a central role in cellular stress responses:
- Oxidative stress: Nitrated vimentin accumulates in PD and AD PMID: 19014939(https://pubmed.ncbi.nlm.nih.gov/19014939/)
- ER stress: Vimentin reorganization during unfolded protein response PMID: 15159811(https://pubmed.ncbi.nlm.nih.gov/15159811/)
- Autophagy: Vimentin cages around aggresomes PMID: 9748272(https://pubmed.ncbi.nlm.nih.gov/9748272/)
- Apoptosis: Caspase cleavage generates apoptotic fragments PMID: 9748272(https://pubmed.ncbi.nlm.nih.gov/9748272/)
Research Directions
Emerging Areas
Unanswered Questions
- How does vimentin contribute to glial scar formation vs. beneficial astrogliosis?
- Can vimentin be safely targeted without affecting normal CNS function?
- What determines the switch from protective to detrimental vimentin expression?
- How do post-translational modifications alter vimentin's role in disease?
Summary Table
| Disease | Vimentin Change | Clinical Utility | Key Findings |
|---------|-----------------|------------------|--------------|
| AD | ↑ CSF and tissue | Progression marker | Correlates with cognition, plaques |
| PD | ↑ Substantia nigra | Pathology marker | Colocalizes with Lewy bodies |
| ALS | ↑↑ CSF and tissue | Progression marker | TDP-43 interaction |
| MS | ↑↑ Active lesions | Disease activity | BBB disruption marker |
| Glioma | ↑↑↑ Tumor cells | Diagnostic | Diagnostic marker |
Background
The study of Vimentin Biomarker has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Intermediate Filament Marker
Allen Brain Atlas Resources
- [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
- [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
External Links
- [UniProt: P08670 (VIM)](https://www.uniprot.org/uniprotkb/P08670/)
- [GeneCards: VIM](https://www.genecards.org/cgi-bin/carddisp.pl?gene=VIM)
- [NCBI Gene: 7431](https://www.ncbi.nlm.nih.gov/gene/7431)
References
Pathway Diagram
The following diagram shows the key molecular relationships involving Vimentin - Biomarker discovered through SciDEX knowledge graph analysis:
▸Metadataorigin_type: v1_polymorphic_backfill
| slug | biomarkers-vimentin |
| kg_node_id | VIMENTIN |
| entity_type | biomarker |
| origin_type | v1_polymorphic_backfill |
| source_table | wiki_pages |
| wiki_page_id | wp-378ca0d3d6c5 |
| __merged_from | {'merged_at': '2026-05-13', 'unprefixed_id': 'biomarkers-vimentin'} |
| _schema_version | 1 |
No provenance edges found
Use ?embed=1 to load the artifact without SciDEX chrome — suitable for iframing into wiki pages or external sites.
<iframe src="http://scidex.ai/artifact/wiki-biomarkers-vimentin?embed=1" width="100%" height="600" style="border:0;border-radius:8px"></iframe>
[Vimentin - Biomarker](http://scidex.ai/artifact/wiki-biomarkers-vimentin)
http://scidex.ai/artifact/wiki-biomarkers-vimentin